Safety and efficacy of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM).

被引：0
|
作者：
Berenson, James R.
Stampleman, Laura
Bessudo, Alberto
Rosen, Peter
Klein, Leonard M.
Woliver, Thomas B. S.
Flam, Marshall S.
Eshaghian, Shahrooz
Nassir, Youram
Swift, Regina A.
Vescio, Robert A.
机构：
[1] Inst Myeloma & Bone Canc Res, Los Angeles, CA USA
[2] Pacific Canc Care, Salinas, CA USA
[3] Pacific Onc Hem Assoc Inc, Encinitas, CA USA
[4] Roy & Patricia Disney Family Canc Ctr, Burbank, CA USA
[5] Illinois Canc Spclsts, Niles, IL USA
[6] Canc Ctr Santa Barbara, Santa Barbara, CA USA
[7] Hem Onc Grp Fresno Inc, Fresno, CA USA
[8] Compassionate Hem & Onc, Los Angeles, CA USA
[9] Canc Care Inst, Los Angeles, CA USA
[10] James R Berenson MD Inc, West Hollywood, CA USA
[11] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8591
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 1/2 study of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory multiple myeloma (RRMM)
    Berenson, James R.
    Klein, Leonard M.
    Rosen, Peter J.
    Woliver, Thomas B. S.
    Eshaghlan, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma
    Cohen, Alexa
    Spektor, Tanya M.
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall
    Eshaghian, Shahrooz
    Nassir, Youram
    Maluso, Tina
    Swift, Regina A.
    Vescio, Robert
    Berenson, James R.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (01) : 60 - 70
  • [3] a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Berenson, James
    Stampleman, Laura
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Regina, Swift A.
    James, Wang
    Benjamin, Eades
    Spektor, Tanya M.
    Vescio, Robert
    [J]. BLOOD, 2015, 126 (23)
  • [4] A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM)
    Hilger, James D.
    Berenson, James R.
    Klein, Leonard M.
    Bessudo, Alberto
    Rosen, Peter J.
    Eshaghian, Shahrooz
    Chamras, Hilda
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] A PHASE IB STUDY OF ISATUXIMAB PLUS POMALIDOMIDE (POM) AND DEXAMETHASONE (DEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mikhael, J.
    Richardson, P.
    Usmani, S.
    Raje, N.
    Bensinger, W.
    Kanagavel, D.
    Gao, L.
    Ziti-ljajic, S.
    Anderson, K.
    [J]. HAEMATOLOGICA, 2017, 102 : 168 - 168
  • [6] OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses
    Richardson, Paul G.
    Schjesvold, Fredrik H.
    Abdulhaq, Haifaa
    Coriu, Daniel
    Lazzaro, Antonio
    Sonneveld, Pieter
    Kullenburg, Torbjorn
    Harmenberg, Johan
    Thuresson, Marcus
    Byrne, Catriona
    Mateos, Maria-Victoria
    [J]. BLOOD, 2021, 138
  • [7] A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Hilger, James D.
    Klein, Leonard M.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    [J]. BLOOD, 2012, 120 (21)
  • [8] A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Stampleman, Laura V.
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    [J]. BLOOD, 2014, 124 (21)
  • [9] Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma
    Wilson, Lilly
    Cohen, Adam D.
    Weiss, Brendan M.
    Vogl, Dan T.
    Garfall, Alfred L.
    Capozzi, Donna L.
    Mangan, Patricia
    Sanchez, Mary
    Erb, Colleen
    Stadtmauer, Edward
    [J]. BLOOD, 2016, 128 (22)
  • [10] Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM)
    Sonneveld, P.
    Hajek, R.
    Nagler, A.
    Spencer, A.
    Blade, J.
    Robak, T.
    Zhuang, S. H.
    Harousseau, J. L.
    Fruchtman, S.
    Orlowski, R. Z.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345